查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2151959

利用分子核酸檢測技術分析輸血醫學市場規模、佔有率和趨勢的報告：按產品、技術、目標病原體、最終用途、地區和細分市場預測（2026-2033 年）

Molecular Nucleic Acid Testing Transfusion Medicine Market Size, Share & Trends Analysis Report By Product, Technology, By Pathogen Target, By End-use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

利用分子核酸檢測（NAT）的輸血醫學市場概述

預計到 2025 年，全球輸血醫學分子核酸檢測 (NAT) 市場規模將達到 9.961 億美元，到 2026 年將成長至 10.428 億美元，到 2033 年將達到 15.137 億美元，2026 年至 2033 年的複合年成長率為 5.5%。

北美是市場領導者，預計到 2025 年將佔銷售額的 35.8%。人們越來越重視最大限度地降低輸血感染疾病的殘餘風險，這推動了血液和血漿篩檢中分子核酸檢測 (NAT) 的需求。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 全球輸血醫學市場：分子核酸檢測（NAT）的應用－影響因素、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 全球分子核酸檢測（NAT）輸血醫學市場分析工具

第4章 全球輸血醫學市場：基於分子核酸檢測（NAT）的產品特定估算與趨勢分析

  • 全球血液輸注分子核酸檢測（NAT）市場：產品特定趨勢分析
  • 全球輸血醫學分子核酸檢測（NAT）市場：產品規模與趨勢分析，2021-2033年
  • 試劑和耗材
  • 裝置
  • 軟體服務

第5章 全球輸血醫學市場：基於分子核酸檢測（NAT）技術的估計與趨勢分析

  • 全球輸血醫學分子核酸檢測（NAT）市場：依技術分類的趨勢分析
    • 全球輸血醫學分子核酸檢測（NAT）市場：按技術分類的規模和趨勢分析（2021-2033年）
  • 轉錄媒介增幅
  • 基於PCR的核酸擴增檢測

第6章 全球輸血醫學市場：基於分子核酸檢測（NAT）的目標病原體估算和趨勢分析

  • 全球輸血醫學分子核酸檢測（NAT）市場：按目標病原體分類的趨勢分析
    • 全球輸血醫學分子核酸檢測（NAT）市場：按目標病原體分類的規模和趨勢分析，2021-2033年
  • HIV-1 與 HIV-2
  • B型肝炎病毒
  • C型肝炎病毒
  • C型肝炎病毒市場市場估算與預測（2021-2033 年）
  • 西尼羅病毒
  • 其他目標病原體

第7章 全球輸血醫學市場：基於分子核酸檢測（NAT）的最終用途估算與趨勢分析

  • 全球利用分子核酸檢測（NAT）進行輸血的市場：依最終用途分類的趨勢分析。
    • 全球血液輸注分子核酸檢測（NAT）市場：依最終用途分類的規模與趨勢分析，2021-2033年
  • 血庫和血液中心
  • 醫院及輸血中心
  • 集中式供體篩檢實驗室
  • 其他最終用途

第8章：輸血醫學市場－分子核酸檢測（NAT）：區域估算與趨勢分析

  • 區域儀錶板
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 公司和競爭對手的分類
  • 策略規劃
  • 企業市場占有率分析，2025 年
  • 主要認證機構/方案運營機構列表
  • 公司簡介列表
    • F. Hoffmann-La Roche Ltd
    • Grifols, SA
    • GFE
    • Sansure Biotech Inc.
    • Mylab Discovery Solutions Pvt. Ltd.
    • DaAn Gene Co., Ltd.
    • Shanghai Kehua Bio-Engineering Co., Ltd.（KHB）
Product Code: GVR-4-68041-033-4

Molecular (NAT) Transfusion Medicine Market Summary

The global molecular nucleic acid testing (NAT) transfusion medicine market size was valued at USD 996.1 million in 2025 and is projected to grow from USD 1,042.8 million in 2026 to USD 1,513.7 million by 2033, at a CAGR of 5.5% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 35.8% in 2025. The rising emphasis on minimizing residual risk of transfusion-transmissible infections supports demand for molecular nucleic acid testing (NAT) in blood and plasma screening.

Global Molecular NAT Transfusion Medicine Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the molecular nucleic acid testing (NAT) transfusion medicine market report on the basis of product, technology, pathogen target, end-use, and region.

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Reagents and Consumables
  • Instruments
  • Software and Services
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Transcription-Mediated Amplification
  • PCR-Based NAT
  • Pathogen Target Outlook (Revenue, USD Million, 2021 - 2033)
  • HIV-1 and HIV-2
  • Hepatitis B Virus
  • Hepatitis C Virus
  • West Nile Virus
  • Other Pathogen Target
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Blood Banks and Blood Centers
  • Hospitals and Transfusion Centers
  • Centralized Donor-Screening Laboratories
  • Other End Use
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Denmark
    • Sweden
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Technology Segment
    • 1.2.3. Pathogen Target Segment
    • 1.2.4. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Molecular (NAT) Transfusion Medicine
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Global Molecular (NAT) Transfusion Medicine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing adoption of NAT for transfusion-transmitted infection screening
      • 3.2.1.2. Increasing emphasis on reducing residual transfusion-transmission risk
      • 3.2.1.3. Expansion of individual-donation NAT and minipool NAT
      • 3.2.1.4. Increasing adoption of automated high-throughput molecular screening
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High capital and operating costs of NAT platforms
      • 3.2.2.2. Complex validation and regulatory requirements
      • 3.2.2.3. Requirement for specialized laboratory infrastructure
      • 3.2.2.4. High reagent and consumable costs
    • 3.2.3. Market opportunity analysis
  • 3.3. Global Molecular (NAT) Transfusion Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Global Molecular (NAT) Transfusion Medicine Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Molecular (NAT) Transfusion Medicine Market Product Movement Analysis
  • 4.3. Global Molecular (NAT) Transfusion Medicine Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Reagents and Consumables
    • 4.4.1. Reagents and Consumables market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Instruments
    • 4.5.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Software and Services
    • 4.6.1. Software and Services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Molecular (NAT) Transfusion Medicine Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Molecular (NAT) Transfusion Medicine Market Technology Movement Analysis
    • 5.2.1. Global Molecular (NAT) Transfusion Medicine Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 5.3. Transcription-Mediated Amplification
    • 5.3.1. Transcription-Mediated Amplification market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4. PCR-Based NAT
    • 5.4.1. PCR-Based NAT market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Molecular (NAT) Transfusion Medicine Market: Pathogen Target Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Molecular (NAT) Transfusion Medicine Market Pathogen Target Movement Analysis
    • 6.2.1. Global Molecular (NAT) Transfusion Medicine Market Size & Trend Analysis, by Pathogen Target, 2021 to 2033 (USD Million)
  • 6.3. HIV-1 and HIV-2
    • 6.3.1. HIV-1 and HIV-2 market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4. Hepatitis B Virus
    • 6.4.1. Hepatitis B Virus market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Hepatitis C Virus
  • 6.6. Hepatitis C Virus market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. West Nile Virus
    • 6.7.1. West Nile Virus market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8. Other Pathogen Target
    • 6.8.1. Other Pathogen Target market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Global Molecular (NAT) Transfusion Medicine Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Molecular (NAT) Transfusion Medicine Market End Use Movement Analysis
    • 7.2.1. Global Molecular (NAT) Transfusion Medicine Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.3. Blood Banks and Blood Centers
    • 7.3.1. Blood Banks and Blood Centers market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Hospitals and Transfusion Centers
    • 7.4.1. Hospitals and Transfusion Centers market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Centralized Donor-Screening Laboratories
    • 7.5.1. Centralized Donor-Screening Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Other End Use
    • 7.6.1. Other End Use market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Molecular (NAT) Transfusion Medicine Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.6. Netherlands
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Netherlands market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Share Analysis, 2025
  • 9.4. List of Key Certification Providers/Scheme Owners
  • 9.5. Company Profiles/Listing
    • 9.5.1. F. Hoffmann-La Roche Ltd
      • 9.5.1.1. Company overview
      • 9.5.1.2. Financial performance
      • 9.5.1.3. Product benchmarking
      • 9.5.1.4. Strategic initiatives
    • 9.5.2. Grifols, S.A.
      • 9.5.2.1. Company overview
      • 9.5.2.2. Financial performance
      • 9.5.2.3. Product benchmarking
      • 9.5.2.4. Strategic initiatives
    • 9.5.3. GFE
      • 9.5.3.1. Company overview
      • 9.5.3.2. Financial performance
      • 9.5.3.3. Product benchmarking
      • 9.5.3.4. Strategic initiatives
    • 9.5.4. Sansure Biotech Inc.
      • 9.5.4.1. Company overview
      • 9.5.4.2. Financial performance
      • 9.5.4.3. Product benchmarking
      • 9.5.4.4. Strategic initiatives
    • 9.5.5. Mylab Discovery Solutions Pvt. Ltd.
      • 9.5.5.1. Company overview
      • 9.5.5.2. Financial performance
      • 9.5.5.3. Product benchmarking
      • 9.5.5.4. Strategic initiatives
    • 9.5.6. DaAn Gene Co., Ltd.
      • 9.5.6.1. Company overview
      • 9.5.6.2. Financial performance
      • 9.5.6.3. Product benchmarking
      • 9.5.6.4. Strategic initiatives
    • 9.5.7. Shanghai Kehua Bio-Engineering Co., Ltd. (KHB)
      • 9.5.7.1. Company overview
      • 9.5.7.2. Financial performance
      • 9.5.7.3. Product benchmarking
      • 9.5.7.4. Strategic initiatives

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviation
  • TABLE 3 Global Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 4 Global Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 5 Global Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 6 Global Molecular (NAT) Transfusion Medicine Market, by End Use, 2021 - 2033 (USD Million)
  • TABLE 7 North America Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 8 North America Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 9 North America Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 10 North America Molecular (NAT) Transfusion Medicine Market, by End Use, 2021 - 2033 (USD Million)
  • TABLE 11 U.S. Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 12 U.S. Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 13 U.S. Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 14 U.S. Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 15 Canada Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 16 Canada Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 17 Canada Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 18 Canada Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 19 Mexico Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 20 Mexico Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 21 Mexico Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 22 Mexico Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 23 Europe Molecular (NAT) Transfusion Medicine Market, by region, 2021 - 2033 (USD Million)
  • TABLE 24 Europe Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 25 Europe Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 26 Europe Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 27 Europe Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 28 UK Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 29 UK Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 30 UK Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 31 UK Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 32 Germany Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 33 Germany Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 34 Germany Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 35 Germany Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 36 France Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 37 France Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 38 France Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 39 France Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 40 Italy Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 41 Italy Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 42 Italy Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 43 Italy Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 44 Spain Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 45 Spain Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 46 Spain Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 47 Spain Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 48 Denmark Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 49 Denmark Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 50 Denmark Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 51 Denmark Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 52 Sweden Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 53 Sweden Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 54 Sweden Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 55 Sweden Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 56 Netherlands Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 57 Netherlands Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 58 Netherlands Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 59 Netherlands Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 60 Asia Pacific Molecular (NAT) Transfusion Medicine Market, by region, 2021 - 2033 (USD Million)
  • TABLE 61 Asia Pacific Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 62 Asia Pacific Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 63 Asia Pacific Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 64 Asia Pacific Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 65 Japan Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 66 Japan Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 67 Japan Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 68 Japan Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 69 China Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 70 China Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 71 China Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 72 China Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 73 India Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 74 India Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 75 India Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 76 India Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 77 Australia Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 78 Australia Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 79 Australia Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 80 Australia Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 81 South Korea Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 82 South Korea Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 83 South Korea Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 84 South Korea Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 85 Thailand Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 86 Thailand Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 87 Thailand Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 88 Thailand Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 89 Latin America Molecular (NAT) Transfusion Medicine Market, by region, 2021 - 2033 (USD Million)
  • TABLE 90 Latin America Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 91 Latin America Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 92 Latin America Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 93 Latin America Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 94 Brazil Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 95 Brazil Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 96 Brazil Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 97 Brazil Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 98 Argentina Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 99 Argentina Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 100 Argentina Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 101 Argentina Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 102 MEA Molecular (NAT) Transfusion Medicine Market, by region, 2021 - 2033 (USD Million)
  • TABLE 103 MEA Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 104 MEA Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 105 MEA Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 106 MEA Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 107 South Africa Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 108 South Africa Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 109 South Africa Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 110 South Africa Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 111 Saudi Arabia Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 112 Saudi Arabia Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 113 Saudi Arabia Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 114 Saudi Arabia Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 115 UAE Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 116 UAE Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 117 UAE Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 118 UAE Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)
  • TABLE 119 Kuwait Molecular (NAT) Transfusion Medicine Market, by product, 2021 - 2033 (USD Million)
  • TABLE 120 Kuwait Molecular (NAT) Transfusion Medicine Market, by technology, 2021 - 2033 (USD Million)
  • TABLE 121 Kuwait Molecular (NAT) Transfusion Medicine Market, by pathogen target, 2021 - 2033 (USD Million)
  • TABLE 122 Kuwait Molecular (NAT) Transfusion Medicine Market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig 1. Market research process
  • Fig 2. Data triangulation techniques
  • Fig 3. Primary research pattern
  • Fig 4. Market research approaches
  • Fig 5. Value-chain-based sizing & forecasting
  • Fig 6. QFD modelling for market share assessment
  • Fig 7. Market formulation & validation
  • Fig 8. Molecular (NAT) Transfusion Medicine Market: Market outlook
  • Fig 9. Molecular (NAT) Transfusion Medicine Market: Competitive insights
  • Fig 10. Parent market outlook
  • Fig 11. Related/ancillary market outlook
  • Fig 12. Penetration and growth prospect mapping
  • Fig 13. Industry value chain analysis
  • Fig 14. Molecular (NAT) Transfusion Medicine Market driver impact
  • Fig 15. Molecular (NAT) Transfusion Medicine Market restraint impact
  • Fig 16. Molecular (NAT) Transfusion Medicine Market strategic initiatives analysis
  • Fig 17. Molecular (NAT) Transfusion Medicine Market: Product movement analysis
  • Fig 18. Molecular (NAT) Transfusion Medicine Market: Product outlook and key takeaways
  • Fig 19. Reagents and Consumables market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 20. Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 21. Software and Services market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 22. Molecular (NAT) Transfusion Medicine Market: Technology movement analysis
  • Fig 23. Molecular (NAT) Transfusion Medicine Market: Technology outlook and key takeaways
  • Fig 24. Transcription-Mediated Amplification market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 25. PCR-Based NAT market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 26. Molecular (NAT) Transfusion Medicine Market: Pathogen Target movement analysis
  • Fig 27. Molecular (NAT) Transfusion Medicine Market: Pathogen Target outlook and key takeaways
  • Fig 28. HIV-1 and HIV-2 market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 29. Hepatitis B Virus market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 30. Hepatitis C Virus market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 31. West Nile Virus market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 32. Other Pathogen Target market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 33. Molecular (NAT) Transfusion Medicine Market: End use movement analysis
  • Fig 34. Molecular (NAT) Transfusion Medicine Market: End use outlook and key takeaways
  • Fig 35. Blood Banks and Blood Centres market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 36. Hospitals and Transfusion Centres market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 37. Centralized Donor-Screening Laboratories market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 38. Other End Use market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 39. Global Molecular (NAT) Transfusion Medicine Market: Regional movement analysis
  • Fig 40. Global Molecular (NAT) Transfusion Medicine Market: Regional outlook and key takeaways
  • Fig 41. North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 42. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 43. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 44. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 45. Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 46. UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 47. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 48. France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 49. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 50. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 51. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 52. Netherlands market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 53. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 54. Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 55. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 56. China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 57. India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 58. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 59. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 60. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 61. Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 62. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 63. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 64. Middle East and Africa. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 65. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 66. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 67. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig 68. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)